tbuckley/cabot-search huggingface dataset:
FRI0439 Psychiatric disorders associated with ankylosing spondylitis
Authors: FG Yurdakul, Y Garip, R Ulucaköy Koçak, E Almaz, A Uçkun, H Bodur
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Ankylosing spondylitis (AS) is an inflammatory rheumatic disease characterized by spinal and/or peripheral involvement, enthesitis, dactylitis, and several extra-articular manifestations. Chronic inflammation often leads to reduced spinal mobility and functional disability. The frequency of fatigue, sleep disturbance, and psychological problems has increased in AS patients (1,2). <h3>Objectives</h3> Although there are studies investigating depression and anxiety frequency in AS patients, different psychiatric disorders such as impulsivity, alexithymia and eating disorders have not been evaluated. The aim of this study is to investigate the frequency of different psychiatric disorders in AS patients, and to evaluate the relationship between these disorders with disease activity and functional status. <h3>Methods</h3> Patients with AS (n=70) and healthy controls (n=56) were included in the study. The <i>Ankylosing Spondylitis Disease Activity Score</i> (<i>ASDAS</i>), Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index (BASMI), pain visual analog scale, Beck depression scale, Beck anxiety scale, Barrat impulsiveness scale, Toronto alexithymia scale, Eating attitude test, fatigue, Ankylosing spondylitis quality of life, and Nothingam health profile were administered. <h3>Results</h3> The frequency of depression, anxiety and non planning impulsiveness were higher in patients with AS than in healthy controls (p&lt;0.05), although no difference was found in terms of alexithymia, fatigue, and eating attitude. Depression and anxiety were correlated with high disease activity, fatigue, impaired physical functioning, and lower quality of life in the patients with AS. Non planning impulsiveness was correlated with fatigue and lower quality of life while there was no correlation with disease activity and functional impairment. BASMI scores were not associated with psychiatric disorders. <h3>Conclusions</h3> Depression and anxiety were associated with disease activation, while impulsivity frequency was increased independently of disease activity. Reducing in the quality of life and functional competence due to the psychiatric disorders indicates that, AS patients may require a psychological care approach during the follow up. <h3>References</h3> Anxiety and depression correlate with disease and quality-of-life parameters in Chinese patients with ankylosing spondylitis.Xu X, Shen B, Zhang A, Liu J, Da Z, Liu H, Gu Z. Patient Prefer Adherence(2016) 20;10:879–85. doi: 10.2147/PPA.S86612. Relationship between psychiatric status, self-reported outcome measures, and clinicalparameters in axial spondyloarthritis. Kilic G, Kilic E, Ozgocmen S. Medicine (Baltimore) (2014) doi: 10.1097/MD.0000000000000337. <h3>Disclosure of Interest</h3> None declared
THU0358 Rosuvastatin improves nitric oxide and endothelial function and suppresses inflammatory disease activity in ankylosing spondylitis
Authors: A Syngle, N Garg, P Krishan
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Nitric oxide (NO) regulates the synthesis of several inflammatory mediators, functions of inflammatory cells in the inflamed joint and plays a central role in the regulation of blood vessel tone<sup>1</sup>. Therefore, NO inhibitors represent important therapeutic advancement in the management of inflammatory diseases. Rosuvastatin improves NO and endothelial dysfunction in patients with heart failure<sup>2</sup> but its effect on NO has not yet been tested in Ankylosing Spondylitis (AS) patients. <h3>Objectives</h3> To investigate the effect of rosuvastatin on nitrite levels (NO surrogate) and its relationship with endothelial function and inflammatory measures in AS. <h3>Methods</h3> 40 consecutive patients (20 in Rosuvastatin (10 mg/day) and 20 in placebo arm) meeting the modified New York criteria for AS, with active disease despite treatment with conventional synthetic DMARDs were recruited. Serum nitrite estimation was carried out by Griess reaction. Flow-mediated dilatation (FMD) was assessed using AngioDefender. Inflammatory measures included– BASDAI, BASFI, ESR and CRP. Pro-inflammatory cytokines (TNF-α, IL-6 and IL-1) were measured at baseline and after 24 weeks. <h3>Results</h3> After 24 weeks, significant improvement in serum nitrite was observed in rosuvastatin group (5.27±0.26 to 4.11±0.19, p&lt;0.01) compared with placebo (5.47±0.26 to 5.36±0.23, p=0.33). At 24weeks; FMD, TNF-α, and IL-6 improved significantly in rosuvastatin group compared with placebo. At 24 weeks; ESR, CRP, BASDAI and BASFI significantly improved in rosuvastatin group compared with placebo. After treatment with rosuvastatin, nitrite correlated inversely with FMD (r=-0.47, p=0.03) (Fig.1A) and positively with TNF-α (r=0.64, p=0.01) (Fig.1B), CRP (r=0.52, p=0.01) (Fig.1C) and LDL (r=0.54, p=0.01) (Fig.1D). <h3>Conclusions</h3> Rosuvastatin reduced serum nitrite concentration and improved endothelial dysfunction in AS patients. Rosuvastatin lowers the proinflammatory cytokines, especially IL-6 and TNF-α, which downregulates CRP production and thus the production of NO. Rosuvastatin also favorably improved the lipid levels in AS patients. Rosuvastatin exerts anti-inflammatory, immunomodulatory and vasculoprotective effect in ankylosing spondylitis through both cholesterol dependent and cholesterol independent pathways <h3>References</h3> Sharma et al. Inflammopharmacology 2007;15:252–9. Schäfer et al. Arterioscler Thromb Vasc Biol 2005;25:1071–1077. <h3>Acknowledgements</h3> None. <h3>Disclosure of Interest</h3> None declared
AB0153 Deletion of receptor for advanced glycation end products (RAGE) does neither affect auto-antibody production nor development of renal disease in pristane-induced lupus
Authors: N Chevalier, R Rzepka, R Voll
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is characterized by autoantibodies to diverse autoantigens, especially to nuclear components such as double-stranded DNA (dsDNA) or nucleosomes. Still, it remains unclear why poorly immunogenic molecules such as dsDNA and nucleosomes become targets of humoral autoimmunity in SLE. Increased signaling via pattern-recognition receptors (PRRs) through pathogen-associated molecular patterns (PAMPs) or endogenous damage-associated molecular patterns (DAMPs) released from damaged or stressed host cells and tissues, may be critically involved in the break of tolerance against such nuclear antigens. One important PRR in this context may be RAGE. Among many others, RAGE recognizes High mobility group box 1 (HMGB1). HMGB1 is a DNA-binding nuclear protein that has been found at elevated levels in patients with SLE and other autoimmune diseases; likewise perpetuation of RAGE signaling sustains inflammation and leads to the establishment of chronic inflammatory disorders. <h3>Objectives</h3> We therefore examined, using the Pristane-induced SLE model, if increased RAGE signaling may be involved in the break of tolerance against nuclear antigens and contributes to chronic inflammation. <h3>Methods</h3> To that end, WT and RAGE-/- animals were injected intra-peritoneally with a single dose of pristane. Disease manifestations were determined after 7 months and included the determination of proteinuria and renal pathology by evaluating the glomerular cellularity and matrix on H&amp;E stained paraffin-embedded kidney sections and glomerular depositions of IgG and C3c. In addition to that we checked for auto-antibody production at several time points during disease development and immune cell distribution, differentiation and phenotype in inflamed kidneys and spleen. <h3>Results</h3> Apart from a slight decrease in GL7<sup>hi</sup>Fas<sup>hi</sup> germinal center B cells and B220<sup>+</sup>CD21<sup>low</sup>CD23<sup>hi</sup> follicular B cells in RAGE-/- animals, we did not detect differences in auto-antibody secretion or disease manifestations between RAGE-/- and WT mice. <h3>Conclusions</h3> Our data contrast with recently published data showing that a deletion of RAGE exacerbated lupus nephritis and lymphoproliferation in a different SLE model (B6-MRL Fas lpr/j). Therefore, we are currently looking into the effects of RAGE deletion in additional models of auto-antibody-mediated immune disease. <h3>Disclosure of Interest</h3> None declared
SAT0422 Effects of vitamin D replacement on the disease activity and inflammatory parameters such as IL-1, IL-6, TNF-α, asymmetric dimethylarginine (ADMA) and arginine/adma ratio in ankylosing spondylitis
Authors: S Ergulu Esmen, S Yılmaz, L Kebapcılar, A Ünlü, SH İpekci, S Abusoglu
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Asymmetric dimethylarginine (ADMA) levels in AS patients were found to be higher than controls (1).The relationship between vitamin D level and disease activity was shown in AS (2). But the effects of vitamin D replacement on the disease acitivity, inflammatory parameters and ADMA pathway were not investigated in AS. <h3>Objectives</h3> To determine the effects of vitamin D replacement on the disease activity, inflammatory parameters and ADMA pathway in AS. <h3>Methods</h3> All AS patients with vitamin D level of &lt;20 ng/ml who consecutively attended the outpatient rheumatology clinic were enrolled.C-reactive protein, erythrocyte sedimentation rate, Bath AS disease activity index (BASDAI), Bath AS Functional Index (BASFI) TNF-α, IL-1, IL-6, ADMA, symmetric dimethylarginine (SDMA), NG-monomethyl-L-arginine (LNMMA), arginine, arginine/ADMA ratio and citrulline levels were analyzed when vitamin D level was &lt;20 ng/ml and ≥20 ng/ml, after replacement. <h3>Results</h3> The study population was represented by 82 patients, 48 women (58.5%), mean age 39 years old and mean disease duration 5.5 years. When vitamin D levels were increased to normal levels, levels of IL-1 (4.8±9.7 and 3.1±4.0 p&lt;0.001), IL-6 (7.1±14.1 and 4.7±2.1 p=0.009), ADMA (0.8±0.2 and 0.4±0.1 p&lt;0.001), SDMA (0.9±0.2 and 0.4±0.2 p&lt;0.001), LNMM (0.08±0.02 and 0.06±0.02 p&lt;0.001), arginine (385.8±106.4 and 269.2±79.0 p&lt;0.001) and citrulline (91,1±34,3 and 75,3±23,5 p&lt;0,001) were reduced. Levels of arginine/ADMA ratio was increased (498.7±136.5 and 576.7±170.7 p&lt;0.001) (Table 1). Also BASDAI, BASFI and erythrocyte sedimentation rate were decreased but it was statistically meaningless. In pearson correlation analysis, ADMA, SDMA, LNMMA, arginine and citrulline were negatively correlated with vitamin D levels.Multiple regression analysis showed that SDMA, arginine and citrulline were significantly related with vitamin D levels. Negative correlation between ADMA and vitamin D levels was shown in Figure 1 <h3>Conclusions</h3> Vitamin D replacement in AS with low vitamin D levels improves antioxidant status via ADMA pathway and shows anti-inflammatory effects on IL-1 and IL-6. In literature, there is no other study investigating the effects of increased vitamin D levels on disease activity, inflammatory parameters and ADMA pathway in AS. <h3>References</h3> Sari I, Kebapcilar L, et al: Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med 2009, 48(16):1363–1368. Lange U, Teichmann J, et al: Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 2005, 16(12):1999–2004. <h3>Disclosure of Interest</h3> None declared
SAT0430 The relationship between exosomal MIRNA21-5P and ankylosing spondylitis
Authors: Y Huang, T Li, Z Huang, W Deng, S Zheng, Z Huang
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Ankylosing Spondylitis (AS) affects human health seriously, which is difficult to diagnose in the early stages. It is reported that MicroRNAs (miRNAs) may serve as novel biomarkers for AS. Exosome can function as vehicles to deliver miRNAs in body fluids including saliva and plasma. Our previous study shows that exosomal miRNA21–5P is higher expressed in AS patients, compared with healthy subjects. However, the relationship between exosomal miRNA21–5P and AS has yet to be determined. <h3>Objectives</h3> The aim of the present study is to explore the relationship between exosomal miRNA21–5P and AS. <h3>Methods</h3> AS patients who fulfilled the modified New York criteria were enrolled for this study. Healthy subjects were also enrolled as control group. BASDAI, BASFI, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were evaluated. Quantitative reverse-transcription PCR (qRT-PCR) was used to confirm the expression of exosomal miRNA21-5P, and receiver-operator characteristic (ROC) curve was used to evaluate the diagnostic value of exosomal miRNA21-5P for AS. According to the cut off value, AS patients were divided into exosomal miRNA21–5P low value group (&lt;cut off value) and exosomal miRNA21-5P high value group (≥cut off value), and the difference of AS patient9s clinical characteristics between the two group were explored. <h3>Results</h3> Twenty healthy subjects and 38 AS patients were enrolled in the study. The qRT-PCR results indicated that the expression level of exsomal miRNA21-5P in AS patients was (2.041±0.975) times higher than that of healthy subjects. ROC curve analysis showed that exsomal miRNA21-5P had significant diagnostic value for AS with the AUC of 0.809 (CI95%: 0.691–0.921). In addition, the cut off value was 1.310, with the specifity of 80.0% and sensitivity of 76.32%. According to the cut off value of exsomal miRNA21–5P, AS patients were divided into the low exsomal miRNA21-5P group (&lt;1.310) and the high exsomal miRNA21-5P group (≥1.310). Among the 38 AS patients, 12 cases were in the low exsomal miRNA21–5P group and 26 cases were in the high exsomal miRNA21-5P group. Comparations of the clinical characteristics of the two groups showed that BASDAI, BASFI, CRP and ESR were significantly increased in exsomal miRNA21-5P high value group. <h3>Conclusions</h3> Exsomal miRNA21-5P was significantly increased in AS patients, which may be used as a biomarker for AS. <h3>References</h3> Atayde VD, Aslan H, Townsend S, Hassani K, Kamhawi S, Olivier M. Exosome. Secretion by the Parasitic Protozoan Leishmania within the Sand Fly Midgut. Cell Reports, 2015, 13 (5): 957–67. <h3>Disclosure of Interest</h3> None declared
FRI0529 Analysis of the evolution of cortical and trabecular bone compartments in the proximal femur after spinal cord injury by 3d-dxa
Authors: L Gifre, L Humbert, A Muxi, L del Rio, J Vidal, E Portell, A Monegal, N Guañabens, P Peris
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Spinal cord injury (SCI) is associated with a marked increase in bone loss and risk of osteoporosis development short-term after injury. 3D-DXA is a new imaging analysis providing volumetric measurements of the cortical and trabecular bone from DXA scans. <h3>Objectives</h3> The aim of this study was to assess the evolution of 3D femoral shape, trabecular macrostructure and cortical bone from DXA scans in patients with recent SCI followed over 12 months. <h3>Methods</h3> 16 males with recent SCI (&lt;3 months since injury) were included. Clinical assessment, bone mineral density (BMD) measurements and 3D-DXA evaluation at proximal femur (analyzing the integral, trabecular and cortical volumetric BMD [vBMD] and cortical thickness) were performed at baseline and at 6 and 12 months of follow-up. <h3>Results</h3> vBMD measured by 3D-DXA significantly decreased at integral, trabecular and cortical compartments at 6 months (-31.1 mg/cm<sup>3</sup>, -8.8%, p&lt;0.001; -25.4 mg/cm<sup>3</sup>, -11.6%, p=0.001; and -20.4 mg/cm<sup>3</sup>, -2.4%, p=0.004), with a further decrease at 12 months, resulting in an overall decrease of -58.9 mg/cm<sup>3</sup> (-16.6%, p&lt;0.001), -47.9 mg/cm<sup>3</sup> (-21.9%, p&lt;0.001) and -42.4 mg/cm<sup>3</sup> (-5%, p&lt;0.001), respectively. Cortical thickness also decreased at 6 and 12 months (-8%, p&lt;0.001; and -11.4%, p&lt;0.001), with the maximal decrease being observed during the first 6 months. The mean BMD loss by DXA at femoral neck and total femur were -17.7% (p&lt;0.001) and -21.1% (p&lt;0.001), at 12-months, respectively. Integral vBMD values at baseline were positively correlated with total femur BMD (r=0.874, p&lt;0.001), however no correlation was observed in the changes in these values at 12-months. <h3>Conclusions</h3> 3D-DXA shows the differentiation of the marked bone loss that occurs at both proximal femoral compartments (cortical and trabecular) short-term after SCI. The present data suggest that 3D-DXA could be a useful complementary assessment tool in SCI patients. <h3>Disclosure of Interest</h3> None declared
Action plan for determining and monitoring the prevalence of chronic kidney disease
Authors: Josef Coresh, Jiun-Ruey Hu, Aminu K. Bello, Harold I. Feldman, Agnes B. Fogo, Mohammad Reza Ganji, David C. Harris, Andrew S. Levey, Ikechi G. Okpechi, Benedicte Stengel, Bernadette Thomas, Andrzej Wiecek, Ron T. Gansevoort
Journal: Kidney International Supplements (2017)
A novel quantified bitterness evaluation model for traditional Chinese herbs based on an animal ethology principle
Authors: Xue Han, Hong Jiang, Li Han, Xi Xiong, Yanan He, Chaomei Fu, Runchun Xu, Dingkun Zhang, Junzhi Lin, Ming Yang
Journal: Acta Pharmaceutica Sinica B (2017)

Traditional Chinese herbs (TCH) are currently gaining attention in disease prevention and health care plans. However, their general bitter taste hinders their use. Despite the development of a variety of taste evaluation methods, it is still a major challenge to establish a quantitative detection technique that is objective, authentic and sensitive. Based on the two-bottle preference test (TBP), we proposed a novel quantitative strategy using a standardized animal test and a unified quantitative benchmark. To reduce the difference of results, the methodology of TBP was optimized. The relationship between the concentration of quinine and animal preference index (PI) was obtained. Then the PI of TCH was measured through TBP, and bitterness results were converted into a unified numerical system using the relationship of concentration and PI. To verify the authenticity and sensitivity of quantified results, human sensory testing and electronic tongue testing were applied. The quantified results showed a good discrimination ability. For example, the bitterness of Coptidis Rhizoma was equal to 0.0579 mg/mL quinine, and Nelumbinis Folium was equal to 0.0001 mg/mL. The validation results proved that the new assessment method for TCH was objective and reliable. In conclusion, this study provides an option for the quantification of bitterness and the evaluation of taste masking effects.
AB0234 Oral contraceptives, menopause and rheumatoid arthritis in korean women: a nationwide study
Authors: JH Jung, HS Jeong, J-H Kim, GG Song, SJ Choi, YH Seo
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease with a multifactorial etiology. Hormonal factors, ethnicity and their interaction may result in the development of RA. <h3>Objectives</h3> We investigated the effects of oral contraceptives (OCs) and menopause on RA in South Korea women using nationwide data. <h3>Methods</h3> Data were collected from the 2008–2012 Korea National Health and Nutrition Examination Surveys. A total of 17,890 eligible participants were included. As there were significant differences in baseline characteristics between the patients on OCs and those not taking OCs, we used propensity score-matching to adjust for such differences. We calculated the odds ratios (ORs) and 95% confidence intervals (95% CIs) of OCs leading to RA development. <h3>Results</h3> The peak incidence of RA was between 50–59 years old. The overall rate of OC usage was 16.5% and mean duration of OC using was 18.41±28.78 (ranged from 0 to 360) months. Before propensity score-matching, using multivariable logistic regression adjusted for traditional risk factors, taking OC was a significantly associated with RA development (OR 1.18, 95% CI 1.18–1.19, <i>p</i> &lt;0.001). After propensity score-matching, taking OCs was not associated with RA (OR 1.05, 95% CI 0.83–1.34, <i>p</i> &lt;0.001). Menopausal status showed strongly significant increase in the risk of RA. <h3>Conclusions</h3> There was an association between menopausal status and RA development in South Korean women. However, usage of OCs did not show significant effects on the development of RA. <h3>References</h3> Pikwer M, Bergstrom U, Nilsson JA, Jacobsson L, Berglund G, Turesson C. Breast feeding, but not use of oral contraceptives, is associated with a reduced risk of rheumatoid arthritis. Ann Rheum Dis 2009;68:526–30. Hazes JM, van Zeben D. Oral contraception and its possible protection against rheumatoid arthritis. Ann Rheum Dis 1991;50:72–4. Pullerits R, d9Elia HF, Tarkowski A, Carlsten H. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. Rheumatology (Oxford) 2009;48:785–90. Doran MF, Crowson CS, O9Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol 2004;31:207–13. <h3>Disclosure of Interest</h3> None declared